Etomidate: Difference between revisions
(→Source) |
(→Source) |
||
| Line 11: | Line 11: | ||
==Source== | ==Source== | ||
#Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med. 2010;56(2):105-113. | #Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med. 2010;56(2):105-113. | ||
==See Also== | |||
*[[Critical care quick reference]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 21:27, 19 December 2014
RSI
0.3 mg/kg bolus IV {Adult standard = 20mg)
Procedural Sedation
0.15 mg/kg bolus IV (Adult standard = 10mg)
Controversy
"The available evidence suggests that etomidate suppresses adrenal function transiently without demonstrating a significant effect on mortality. However, no studies to date have been powered to detect a difference in hospital, ventilator, or ICU length of stay or in mortality."
Source
- Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med. 2010;56(2):105-113.